Term
| beta 2 receptor agonist PD, effect, uses |
|
Definition
| increase cAMP by activating Gs protein which decreases cytosolic Ca...also decreases histamine and LT release; relaxes smooth muscle and mild anti-inflammatory; for asthma (COPD), uterus relaxation (delays birth/also use Mg), hyperkalemia (squeezes K into cell, insulin/dextrose is first-line tx) |
|
|
Term
|
Definition
| beta 2 agonists, smooth muscle relaxation |
|
|
Term
| Albuterol mode of action, onset/offset, use, side effect, secretion, good guy: R/S isomer? |
|
Definition
| beta-2 agonist; rapid onset/short acting (ROSA); asthma reliever (2-4 hr); tachycardia (some beta 1 action); renal secretion; R = eutomer, more affinity for beta 2 than distomer (L) |
|
|
Term
| levalbuterol mode of action, onset/offset, use, side effect |
|
Definition
| only eutomer version of albuterol beta-2 agonist; rapid onset/short acting (ROSA); asthma reliever (2-4 hr); less tachycardia (more selective for beta 2 than beta 1 than albuterol) |
|
|
Term
| ROSA beta 2 agonists, use |
|
Definition
| bambuterol -> terbutalin, fenoterol, reproterol, pirbuterol, bitolterol -> colterol (slow onset); asthma relievers (2-4 hr) |
|
|
Term
| Long acting beta 2 agonists, use, current trend? |
|
Definition
| salmeterol, formoterol; asthma controllers (> 10 hr), move toward anti-inflammatory steroids as controllers |
|
|
Term
| Salmeterol mode of action, use, onset/offset |
|
Definition
| partial beta 2 agonists, asthma controller, slow onset/long acting (SOLA) |
|
|
Term
| Formoterol mode of action, use, onset/offset |
|
Definition
| beta 2 agonist; asthma controller OR reliever; rapid onset/long acting (ROLA) |
|
|
Term
| beta 1 receptor agonist PD, effect |
|
Definition
|
|
Term
| dobutamine mode of action, effect, synthetic version of? |
|
Definition
| pseudo beta 1 agonist (alpha 1 agonist and antagonism of racemic mix cancel); inotropic used by surgeons; synthetic catecholamine |
|
|
Term
| dopamine dose effects: low, medium, high? |
|
Definition
| Low (D1) = renal dose, dilates renal vasculature, increased RPF/perfusion; medium (beta 1) = heart dose, increased heart rate; high (alpha 1) = increased vasoconstriction, afterload and oxygen consumption. |
|
|
Term
| dopexamine mode of action, effect, use, synthetic version of? |
|
Definition
| D1 and beta 2 agonists at low dose, decreases afterload (vasodilation) and O2 consumption, inotropic; synthetic catecholamine (dopamine) |
|
|
Term
| fenoldopam mode of action, use, equivalent to? |
|
Definition
| selective D1 agonist; anti-hypertensive; like low dose dopamine (renal dose) |
|
|
Term
| Isoprenaline mode of action, effect, synthetic version of? |
|
Definition
| non-selective beta agonist; inotropic and vasodilation/decrease afterload (increase in O2 consumption more moderate like PDE III inhibitors); synthetic catecholamine |
|
|
Term
|
Definition
| Intrinsic sympathomimetic activity; less likely to overdose on beta blockers with this (blockers also partial agonists), no increase in TG, LDL or glucose |
|
|
Term
| selective beta 1 blockers effect, at high doses,examples? |
|
Definition
| slow heart without vascular effect; lose selectivity at high doses; metaprolol, atenolol, acebutolol |
|
|
Term
| Beta blocker effect, side effects? for overdose? |
|
Definition
| vasodilation; loss of ability to vasodilate (bad for asthma and COPD), increased TG, LDL and glucose (like diuretics), dreams if fat soluble (ex: diuretic propranolol); use inotropic insulin or glucagon for overdose |
|
|
Term
| propranolol mode of action, solubility?, metabolism? ISA? |
|
Definition
| non-selective beta and Na channel blocker; fat soluble (dreams); Hepatatic 1A and 2D6; no ISA |
|
|
Term
| pindolol mode of action, solubility?, metabolism? ISA? |
|
Definition
| non-selective beta and (membrane stabilizing) Na channel blocker, 5HT1a agonist; water soluble; renal excretion; strong ISA |
|
|
Term
| metoprolol mode of action, solubility?, metabolism? ISA? |
|
Definition
| selective beta 1 blocker; fat soluble (dreams); hepatic 2D6; no ISA |
|
|
Term
| atenolol mode of action, solubility?, metabolism? ISA? |
|
Definition
| selective beta 1 blocker; water soluble; renal elimination; no ISA |
|
|
Term
| acebutolol mode of action, solubility?, metabolism? ISA? |
|
Definition
| selective beta 1 and membrane stabilizing Na channel blocker; fat soluble; renal elimination; ISA (also less effect on metabolic profile TG, LDL) |
|
|
Term
| nadolol mode of action, solubility?, metabolism? ISA? |
|
Definition
| non-selective beta blocker; water soluble; renal excretion; no ISA |
|
|
Term
| Water soluble beta blockers? |
|
Definition
| PANS: pindolol, atenolol, nadolol, satalol |
|
|
Term
| esmolol mode of action, delivery?, metabolism? half life? |
|
Definition
| beta blocker; IV, plasma esterases; ultra short acting |
|
|
Term
| beta blockers affect on cardio depolarization |
|
Definition
| Mainly flattens phase 4 (harder to depolarize) |
|
|
Term
| labetalol mode of action, effect, |
|
Definition
| mixed: non-cardio selective alpha/beta blocker and more; mainly reduces afterload and bronchoconstriction (alpha blocker) |
|
|
Term
| carvedilol mode of action, effect |
|
Definition
| mixed non-cardioselective alpha/beta blocker; stops vasculature from contracting (alpha blocker) |
|
|
Term
| Nebivolol mode of action, metabolism |
|
Definition
| beta blocker with NO (an EDRF) potentiating effect; metabolism by 2D6 to active moieties. NOTE EDRF = endothelium derived relaxing factor |
|
|
Term
| For beta blocker overdose? |
|
Definition
| Use inotrope insulin or glucagon (can't use beta agonist because receptor blocked) |
|
|
